Latest Breaking News On - Stony brookny neurosciences institute - Page 1 : comparemela.com

Ublituximab is superior to teriflunomide in suppressing multiple sclerosis relapses and lesions on MRI, suggest findings from the phase 3 ULTIMATE I and II trials.

Lawrence steinmanViela bioGenentech rochePatricia coyleSanofi genzymeStanford calif universityMs comprehensive care centerBristol myers squibbStony brookny neurosciences instituteNew england journalCare centerStony brookNeurosciences instituteMultiple sclerosis msMultiple sclerosisIntravenous iv